Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Mainz Biomed B.V. ( (MYNZ)) has ...
Mainz Biomed NV has announced that it has regained compliance with Nasdaq's minimum stockholders’ equity requirement, confirming its continued listing on the Nasdaq Capital Market. This follows the ...
BERKELEY, Calif. and MAINZ, Germany, May 24, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early ...
BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce ...
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 01.10.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement ...
Mainz Biomed N.V. (NASDAQ:MYNZ) announced a 1-for-40 reverse stock split, effective Dec. 3. The company specializes in the early detection of cancer. Last month, Mainz Biomed reported a collaborative ...
BERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its ...
BERKELEY, Calif. and MAINZ, Germany, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early ...
The molecular genetics diagnostic company's flagship product ColoAlert is an early detection screening that spots bleeding and non-bleeding tumors through tumor DNA analysis. ColoAlert analyzes ...
Mainz Biomed and Thermo Fisher Scientific signed a collaboration agreement for the development of the Company’s next generation colorectal cancer (CRC) screening product for global markets. The ...
BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
Molecular genetics diagnostic company Mainz (Germany) Biomed has submitted an application for breakthrough device designation from the FDA for a colorectal cancer screening test. If granted, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results